查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597564

全球抗體/重組蛋白 CDMO 市場：按類型、來源類型、生產規模、應用、最終用戶、地區 - 趨勢分析、競爭格局、預測（2019-2030）

Antibody and Recombinant Protein CDMO Market, By Type; By Source Type; By Scale of Production; By Application; By End User, By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 530 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2030年全球抗體和重組蛋白CDMO市場規模預計將超過350億美元

由於對合約生物製藥開發和製造服務的需求不斷增加，以及生技藥品製造過程的複雜性不斷增加，全球抗體和重組蛋白 CDMO 市場正在蓬勃發展。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2023 年全球抗體和重組蛋白 CDMO 市場規模為 167 億美元。 BlueWeave預測，2024-2030年期間，全球抗體和重組蛋白CDMO市場將以11.2%的複合年成長率成長，到2030年達到354億美元。全球抗體和重組蛋白 CDMO 市場的關鍵成長要素是對生技藥品和重組蛋白治療藥物的需求不斷成長。此外，包括糖尿病和癌症在內的各種慢性疾病的盛行率上升、科學突破以及生物製藥領域投資的增加將推動預測期內全球抗體和重組蛋白 CDMO 市場的成長。

機會：重大收購和併購

許多受託製造廠商(CDMO) 正在進行併購以擴展其現有能力。小型公司正在合併以利用技術和平台，而中型公司則專注於透過這些策略聯盟實現管道多元化。例如，美國CDMO公司Curia最近收購了製劑和灌裝加工公司完整性 Bio。另一個例子是，Delpharm 宣布將從Astellas Pharma 手中收購荷蘭 Meppel 製藥廠，從而加強其在該國的 CDMO 地位。在分析期間，此類發展預計將為全球抗體和重組蛋白 CDMO 市場提供利潤豐厚的成長機會。

地緣政治緊張局勢加劇對全球抗體和重組蛋白 CDMO 市場的影響

關鍵地區國家之間地緣政治緊張局勢的加劇可能會為全球抗體和重組蛋白 CDMO 市場帶來前所未有的挑戰。地緣政治緊張局勢對市場運作的一個重大影響是供應鏈的中斷，使得獲得製造抗體和重組蛋白所需的原料和試劑變得更加困難。許多出口國可能會施加關稅和貿易限制，這可能會使 CDMO 的採購技術變得更加困難。由於衝突或加強安全措施而導致的物流和運輸延誤可能會影響預定的產品交付。緊張局勢升級可能導致法律規範收緊，進而影響 CDMO 開展跨國業務的能力。

治療藥物領域佔據大部分市場佔有率

治療藥物領域在全球抗體和重組蛋白 CDMO 市場中佔有最大佔有率。生活方式的改變和老年人口的增加正在增加各種慢性疾病的盛行率，增加了對用於治療目的的重組蛋白療法的需求。重組蛋白療法廣泛用於治療各種類型的癌症。隨著全球癌症盛行率的不斷增加，對重組蛋白的需求預計只會增加。

北美在全球市場佔據主導地位

北美主導全球抗體和重組蛋白 CDMO 市場。該地區的市場擴張得到了美國和加拿大強大的醫療保健系統以及重要生物技術和製藥公司集中的支持。然而，亞太地區預計在預測期內將出現顯著成長。亞太地區抗體和重組蛋白 CDMO 市場預計將受到該地區不斷成長的醫療保健支出和不斷增加的研發舉措的推動。

競爭格局

全球抗體和重組蛋白 CDMO 市場的主要行業參與者包括 Batavia Biosciences、Grifols、Cerbios-Pharma SA、HALIX、Biovian Oy、Catalent、Goodwin Biotechnology、Cerbios-Pharma SA、Gene Universal Inc.、Eurogentec、MabPlex International、Etinpro（北京）有限公司等

為了進一步增加市場佔有率，這些公司正在採取各種策略，例如併購、夥伴關係、合資、授權合約和新產品發布。

該報告的詳細分析提供了有關成長潛力、未來趨勢和全球抗體和重組蛋白 CDMO 市場的資訊。它還涵蓋了推動市場總規模預測的因素。該報告致力於提供全球抗體和重組蛋白 CDMO 市場的最新技術趨勢以及產業見解，以幫助決策者做出策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第3章 全球抗體與重組蛋白CDMO市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 生物製藥需求增加
      • 複雜的製造程序
      • 生物技術的不斷進步
    • 抑制因素
      • 監管障礙高
      • 保護智慧財產權
      • 容量限制
    • 機會
      • 醫療基礎設施不斷發展的新興國家
      • 個性化醫療的興起
      • 細胞和基因治療的快速發展
    • 任務
      • 確保生物製藥的品質和一致性
      • 競爭加劇和成本壓力
  • 科技進步/最新趨勢
  • 法律規範
  • 波特五力分析

第4章 全球抗體/重組蛋白CDMO市場：行銷策略

第5章 全球抗體/重組蛋白CDMO市場：價格分析

第6章全球抗體/重組蛋白 CDMO 市場：區域分析

  • 全球抗體/重組蛋白 CDMO 市場：區域分析 (2023)
  • 全球抗體/重組蛋白CDMO市場：市場吸引力分析（2019-2030）

第7章 全球抗體/重組蛋白CDMO市場概況

  • 市場規模及預測（2019-2030）
    • 按金額
  • 市場佔有率及預測
    • 按類型
      • 抗體CDMO
      • 重組蛋白CDMO
    • 按來源類型
      • 哺乳動物的
      • 微生物
      • 其他
    • 按生產規模
      • 臨床製造
      • 商業製造
    • 按用途
      • 治療藥物
      • 研究與開發
      • 診斷
    • 按最終用戶
      • 製藥和生物技術公司
      • 學術研究所
      • 合約研究組織（CRO）
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第8章 北美抗體/重組蛋白CDMO市場

  • 市場規模及預測（2019-2030）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按來源類型
    • 按生產規模
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第9章 歐洲抗體/重組蛋白CDMO市場

  • 市場規模及預測（2019-2030）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按來源類型
    • 按生產規模
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第10章亞太抗體/重組蛋白CDMO市場

  • 市場規模及預測（2019-2030）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按來源類型
    • 按生產規模
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

第11章拉丁美洲抗體/重組蛋白CDMO市場

  • 市場規模及預測（2019-2030）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按來源類型
    • 按生產規模
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第12章中東與非洲抗體/重組蛋白CDMO市場

  • 市場規模及預測（2019-2030）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按來源類型
    • 按生產規模
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第13章競爭格局

  • 主要企業/產品列表
  • 全球抗體/重組蛋白CDMO企業市場佔有率分析（2023年）
  • 競爭基準化分析：管理參數
  • 重大策略發展（合併、收購、聯盟等）

第14章 地緣政治緊張局勢升級對全球抗體和重組蛋白CDMO市場的影響

第15章 公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人員、主要競爭對手、聯絡地址、策略展望、SWOT分析）

  • Batavia Biosciences
  • Grifols
  • Cerbios-Pharma SA
  • HALIX
  • Biovian Oy
  • Catalent
  • Goodwin Biotechnology
  • Cerbios-Pharma SA
  • Gene Universal Inc.
  • Eurogentec
  • MabPlex International
  • Etinpro（Beijing）Co
  • 其他主要企業

第16章 主要策略建議

第17章調查方法

簡介目錄
Product Code: BWC24833

Global Antibody and Recombinant Protein CDMO Market to Cross USD 35 Billion by 2030

Global Antibody and Recombinant Protein CDMO Market is flourishing because of a rising demand for biopharma contract development and manufacturing services and increasingly complex processes involved in producing biologics.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Antibody and Recombinant Protein CDMO Market size at USD 16.70 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Antibody and Recombinant Protein CDMO Market size to expand at a CAGR of 11.2% reaching a value of USD 35.40 billion by 2030. Major growth factors for Global Antibody and Recombinant Protein CDMO Market include an increasing need for biologics and recombinant protein therapies. Over the forecast period, it is also expected that the growth of Global Antibody and Recombinant Protein CDMO Market will be spurred by the rising incidence of various chronic illnesses, including diabetes and cancer, scientific breakthroughs, and rising investments biopharmaceutical sector.

Opportunity - Major Acquisitions and Mergers

Many contract development and manufacturing organizations (CDMOs) are entering into mergers and acquisitions to expand their existing capacities. Small companies merge to leverage technology and platforms, while mid-size companies focus on diversifying pipelines through these strategic alliances. For instance, Curia, an American CDMO company, recently acquired Integrity Bio, a formulation and fill-finish company. In another example, Delpharm announced the acquisition of the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas to strengthen CDMO's position in the country. Such developments are anticipated to provide lucrative growth opportunities to global antibody and recombinant protein CDMO market during the period in analysis.

Impact of Escalating Geopolitical Tensions on Global Antibody and Recombinant Protein CDMO Market

Intensifying geopolitical tensions among countries spreading across the major regions could bring unprecedented challenges for Global Antibody and Recombinant Protein CDMO Market. A significant effect of geopolitical tensions on market operations is supply chain disruption, which makes it more difficult to get the necessary raw materials and reagents for the manufacturing of antibodies and recombinant proteins. Many exporting nations may apply tariffs or trade restrictions, which might make CDMOs' sourcing techniques more difficult. Product delivery on schedule may be impacted by delays in logistics and transportation caused by conflicts or increased security measures. Increased tensions may result in more stringent regulatory frameworks, which would affect CDMOs' capacity to conduct cross-border operations.

Therapeutics Segment Accounts for Major Market Share

The therapeutics segment holds the largest share of Global Antibody and Recombinant Protein CDMO Market. The growing prevalence of various chronic diseases owing to changing lifestyles and the rising geriatric populations is fueling the demand for recombinant protein therapeutics for treatment purposes. Recombinant protein therapeutics are widely used to treat various types of cancer. With the increasing prevalence of cancer worldwide, the demand for recombinant proteins is projected to rise only.

North America Holds Leadership Position in Global Market

North America dominates Global Antibody and Recombinant Protein CDMO Market. Expansion of the regional market is aided by the concentration of significant biotechnology and pharmaceutical firms as well as the strong healthcare systems in United States and Canada. However, over the forecast period, the Asia Pacific region is expected to register a significant growth rate. The Asia Pacific Antibody and Recombinant Protein CDMO Market is expected to be driven by the region's growing healthcare spending as well as an increase in research and development initiatives.

Competitive Landscape

Major industry players of Global Antibody and Recombinant Protein CDMO Market include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Cerbios-Pharma SA, Gene Universal Inc., Eurogentec, MabPlex International, and Etinpro (Beijing) Co.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Antibody and Recombinant Protein CDMO Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antibody and Recombinant Protein CDMO Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antibody and Recombinant Protein CDMO Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Demand for Biologics
      • 3.2.1.2. Complex Manufacturing Processes
      • 3.2.1.3. Continuous Advancements in Biotechnology
    • 3.2.2. Restraints
      • 3.2.2.1. High Regulatory Hurdles
      • 3.2.2.2. Protecting Intellectual Property Rights
      • 3.2.2.3. Capacity Constraints
    • 3.2.3. Opportunities
      • 3.2.3.1. Developing Countries with Growing Healthcare Infrastructure
      • 3.2.3.2. Rise of Personalized Medicine
      • 3.2.3.3. Rapid Development of Cell and Gene Therapies
    • 3.2.4. Challenges
      • 3.2.4.1. Ensuring the Quality and Consistency of Biologic Products
      • 3.2.4.2. Increasing Competition and Cost Pressures
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antibody and Recombinant Protein CDMO Market: Marketing Strategies

5. Global Antibody and Recombinant Protein CDMO Market: Pricing Analysis

6. Global Antibody and Recombinant Protein CDMO Market: Geographical Analysis

  • 6.1. Global Antibody and Recombinant Protein CDMO Market, Geographical Analysis, 2023
  • 6.2. Global Antibody and Recombinant Protein CDMO Market, Market Attractiveness Analysis, 2019-2030

7. Global Antibody and Recombinant Protein CDMO Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
      • 7.2.1.1. Antibody CDMO
      • 7.2.1.2. Recombinant Protein CDMO
    • 7.2.2. By Source Type
      • 7.2.2.1. Mammalian
      • 7.2.2.2. Microbial
      • 7.2.2.3. Others
    • 7.2.3. By Scale of Production
      • 7.2.3.1. Clinical Manufacturing
      • 7.2.3.2. Commercial Manufacturing
    • 7.2.4. By Application
      • 7.2.4.1. Therapeutics
      • 7.2.4.2. Research & Development
      • 7.2.4.3. Diagnostics
    • 7.2.5. By End User
      • 7.2.5.1. Pharmaceutical & Biotechnology Companies
      • 7.2.5.2. Academic & Research Institutes
      • 7.2.5.3. Contract Research Organizations (CROs)
    • 7.2.6. By Region
      • 7.2.6.1. North America
      • 7.2.6.2. Europe
      • 7.2.6.3. Asia Pacific (APAC)
      • 7.2.6.4. Latin America (LATAM)
      • 7.2.6.5. Middle East and Africa (MEA)

8. North America Antibody and Recombinant Protein CDMO Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Source Type
    • 8.2.3. By Scale of Production
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
      • 8.2.6.1. United States
      • 8.2.6.1.1. By Type
      • 8.2.6.1.2. By Source Type
      • 8.2.6.1.3. By Scale of Production
      • 8.2.6.1.4. By Application
      • 8.2.6.1.5. By End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. By Type
      • 8.2.6.2.2. By Source Type
      • 8.2.6.2.3. By Scale of Production
      • 8.2.6.2.4. By Application
      • 8.2.6.2.5. By End User

9. Europe Antibody and Recombinant Protein CDMO Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Source Type
    • 9.2.3. By Scale of Production
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
      • 9.2.6.1. Germany
      • 9.2.6.1.1. By Type
      • 9.2.6.1.2. By Source Type
      • 9.2.6.1.3. By Scale of Production
      • 9.2.6.1.4. By Application
      • 9.2.6.1.5. By End User
      • 9.2.6.2. United Kingdom
      • 9.2.6.2.1. By Type
      • 9.2.6.2.2. By Source Type
      • 9.2.6.2.3. By Scale of Production
      • 9.2.6.2.4. By Application
      • 9.2.6.2.5. By End User
      • 9.2.6.3. Italy
      • 9.2.6.3.1. By Type
      • 9.2.6.3.2. By Source Type
      • 9.2.6.3.3. By Scale of Production
      • 9.2.6.3.4. By Application
      • 9.2.6.3.5. By End User
      • 9.2.6.4. France
      • 9.2.6.4.1. By Type
      • 9.2.6.4.2. By Source Type
      • 9.2.6.4.3. By Scale of Production
      • 9.2.6.4.4. By Application
      • 9.2.6.4.5. By End User
      • 9.2.6.5. Spain
      • 9.2.6.5.1. By Type
      • 9.2.6.5.2. By Source Type
      • 9.2.6.5.3. By Scale of Production
      • 9.2.6.5.4. By Application
      • 9.2.6.5.5. By End User
      • 9.2.6.6. Belgium
      • 9.2.6.6.1. By Type
      • 9.2.6.6.2. By Source Type
      • 9.2.6.6.3. By Scale of Production
      • 9.2.6.6.4. By Application
      • 9.2.6.6.5. By End User
      • 9.2.6.7. Russia
      • 9.2.6.7.1. By Type
      • 9.2.6.7.2. By Source Type
      • 9.2.6.7.3. By Scale of Production
      • 9.2.6.7.4. By Application
      • 9.2.6.7.5. By End User
      • 9.2.6.8. The Netherlands
      • 9.2.6.8.1. By Type
      • 9.2.6.8.2. By Source Type
      • 9.2.6.8.3. By Scale of Production
      • 9.2.6.8.4. By Application
      • 9.2.6.8.5. By End User
      • 9.2.6.9. Rest of Europe
      • 9.2.6.9.1. By Type
      • 9.2.6.9.2. By Source Type
      • 9.2.6.9.3. By Scale of Production
      • 9.2.6.9.4. By Application
      • 9.2.6.9.5. By End User

10. Asia Pacific Antibody and Recombinant Protein CDMO Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Source Type
    • 10.2.3. By Scale of Production
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
      • 10.2.6.1. China
      • 10.2.6.1.1. By Type
      • 10.2.6.1.2. By Source Type
      • 10.2.6.1.3. By Scale of Production
      • 10.2.6.1.4. By Application
      • 10.2.6.1.5. By End User
      • 10.2.6.2. India
      • 10.2.6.2.1. By Type
      • 10.2.6.2.2. By Source Type
      • 10.2.6.2.3. By Scale of Production
      • 10.2.6.2.4. By Application
      • 10.2.6.2.5. By End User
      • 10.2.6.3. Japan
      • 10.2.6.3.1. By Type
      • 10.2.6.3.2. By Source Type
      • 10.2.6.3.3. By Scale of Production
      • 10.2.6.3.4. By Application
      • 10.2.6.3.5. By End User
      • 10.2.6.4. South Korea
      • 10.2.6.4.1. By Type
      • 10.2.6.4.2. By Source Type
      • 10.2.6.4.3. By Scale of Production
      • 10.2.6.4.4. By Application
      • 10.2.6.4.5. By End User
      • 10.2.6.5. Australia & New Zealand
      • 10.2.6.5.1. By Type
      • 10.2.6.5.2. By Source Type
      • 10.2.6.5.3. By Scale of Production
      • 10.2.6.5.4. By Application
      • 10.2.6.5.5. By End User
      • 10.2.6.6. Indonesia
      • 10.2.6.6.1. By Type
      • 10.2.6.6.2. By Source Type
      • 10.2.6.6.3. By Scale of Production
      • 10.2.6.6.4. By Application
      • 10.2.6.6.5. By End User
      • 10.2.6.7. Malaysia
      • 10.2.6.7.1. By Type
      • 10.2.6.7.2. By Source Type
      • 10.2.6.7.3. By Scale of Production
      • 10.2.6.7.4. By Application
      • 10.2.6.7.5. By End User
      • 10.2.6.8. Singapore
      • 10.2.6.8.1. By Type
      • 10.2.6.8.2. By Source Type
      • 10.2.6.8.3. By Scale of Production
      • 10.2.6.8.4. By Application
      • 10.2.6.8.5. By End User
      • 10.2.6.9. Vietnam
      • 10.2.6.9.1. By Type
      • 10.2.6.9.2. By Source Type
      • 10.2.6.9.3. By Scale of Production
      • 10.2.6.9.4. By Application
      • 10.2.6.9.5. By End User
      • 10.2.6.10. Rest of APAC
      • 10.2.6.10.1. By Type
      • 10.2.6.10.2. By Source Type
      • 10.2.6.10.3. By Scale of Production
      • 10.2.6.10.4. By Application
      • 10.2.6.10.5. By End User

11. Latin America Antibody and Recombinant Protein CDMO Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Source Type
    • 11.2.3. By Scale of Production
    • 11.2.4. By Application
    • 11.2.5. By End User
    • 11.2.6. By Country
      • 11.2.6.1. Brazil
      • 11.2.6.1.1. By Type
      • 11.2.6.1.2. By Source Type
      • 11.2.6.1.3. By Scale of Production
      • 11.2.6.1.4. By Application
      • 11.2.6.1.5. By End User
      • 11.2.6.2. Mexico
      • 11.2.6.2.1. By Type
      • 11.2.6.2.2. By Source Type
      • 11.2.6.2.3. By Scale of Production
      • 11.2.6.2.4. By Application
      • 11.2.6.2.5. By End User
      • 11.2.6.3. Argentina
      • 11.2.6.3.1. By Type
      • 11.2.6.3.2. By Source Type
      • 11.2.6.3.3. By Scale of Production
      • 11.2.6.3.4. By Application
      • 11.2.6.3.5. By End User
      • 11.2.6.4. Peru
      • 11.2.6.4.1. By Type
      • 11.2.6.4.2. By Source Type
      • 11.2.6.4.3. By Scale of Production
      • 11.2.6.4.4. By Application
      • 11.2.6.4.5. By End User
      • 11.2.6.5. Rest of LATAM
      • 11.2.6.5.1. By Type
      • 11.2.6.5.2. By Source Type
      • 11.2.6.5.3. By Scale of Production
      • 11.2.6.5.4. By Application
      • 11.2.6.5.5. By End User

12. Middle East & Africa Antibody and Recombinant Protein CDMO Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Source Type
    • 12.2.3. By Scale of Production
    • 12.2.4. By Application
    • 12.2.5. By End User
    • 12.2.6. By Country
      • 12.2.6.1. Saudi Arabia
      • 12.2.6.1.1. By Type
      • 12.2.6.1.2. By Source Type
      • 12.2.6.1.3. By Scale of Production
      • 12.2.6.1.4. By Application
      • 12.2.6.1.5. By End User
      • 12.2.6.2. UAE
      • 12.2.6.2.1. By Type
      • 12.2.6.2.2. By Source Type
      • 12.2.6.2.3. By Scale of Production
      • 12.2.6.2.4. By Application
      • 12.2.6.2.5. By End User
      • 12.2.6.3. Qatar
      • 12.2.6.3.1. By Type
      • 12.2.6.3.2. By Source Type
      • 12.2.6.3.3. By Scale of Production
      • 12.2.6.3.4. By Application
      • 12.2.6.3.5. By End User
      • 12.2.6.4. Kuwait
      • 12.2.6.4.1. By Type
      • 12.2.6.4.2. By Source Type
      • 12.2.6.4.3. By Scale of Production
      • 12.2.6.4.4. By Application
      • 12.2.6.4.5. By End User
      • 12.2.6.5. South Africa
      • 12.2.6.5.1. By Type
      • 12.2.6.5.2. By Source Type
      • 12.2.6.5.3. By Scale of Production
      • 12.2.6.5.4. By Application
      • 12.2.6.5.5. By End User
      • 12.2.6.6. Nigeria
      • 12.2.6.6.1. By Type
      • 12.2.6.6.2. By Source Type
      • 12.2.6.6.3. By Scale of Production
      • 12.2.6.6.4. By Application
      • 12.2.6.6.5. By End User
      • 12.2.6.7. Algeria
      • 12.2.6.7.1. By Type
      • 12.2.6.7.2. By Source Type
      • 12.2.6.7.3. By Scale of Production
      • 12.2.6.7.4. By Application
      • 12.2.6.7.5. By End User
      • 12.2.6.8. Rest of MEA
      • 12.2.6.8.1. By Type
      • 12.2.6.8.2. By Source Type
      • 12.2.6.8.3. By Scale of Production
      • 12.2.6.8.4. By Application
      • 12.2.6.8.5. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Antibody and Recombinant Protein CDMO Company Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Antibody and Recombinant Protein CDMO Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Batavia Biosciences
  • 15.2. Grifols
  • 15.3. Cerbios-Pharma SA
  • 15.4. HALIX
  • 15.5. Biovian Oy
  • 15.6. Catalent
  • 15.7. Goodwin Biotechnology
  • 15.8. Cerbios-Pharma SA
  • 15.9. Gene Universal Inc.
  • 15.10. Eurogentec
  • 15.11. MabPlex International
  • 15.12. Etinpro (Beijing) Co
  • 15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable